Intraductal carcinoma, also known as ductal carcinoma in situ, has a high survival rate if patients are treated with effective active treatment or surgical resection, with a 5-year survival rate of more than 95%, and even long-term survival can be achieved. Patients are advised to follow up closely and review regularly after surgery to prevent recurrence or metastasis. Intraductal carcinoma is a tumorigenic intraductal proliferative lesion with obvious proliferation of tumorigenic epithelial cells, and the cells will be accompanied by heterogeneous proliferative changes from mild to severe, without breaking through the basement membrane, infiltration to the interstitium, or metastasis, etc. Therefore, the prognosis of intraductal carcinoma is very good. Therefore, the prognosis of intraductal carcinoma is very good and can even achieve lifelong cure. Whether intraductal carcinoma will recur or not is closely related to the size of the lesion, whether there is acantholytic necrosis or not, and the condition of the cut edge and so on. Therefore, it is suggested that patients must review regularly to prevent infiltration or metastasis of the disease.